RPHC.F Stock Overview
Manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Rohto Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥21.54 |
| 52 Week High | JP¥22.66 |
| 52 Week Low | JP¥20.49 |
| Beta | -0.21 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -30.17% |
| 5 Year Change | n/a |
| Change since IPO | 63.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPHC.F | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | -5.5% | -4.0% |
| 1Y | n/a | -24.4% | 24.0% |
Return vs Industry: Insufficient data to determine how RPHC.F performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how RPHC.F performed against the US Market.
Price Volatility
| RPHC.F volatility | |
|---|---|
| RPHC.F Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RPHC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RPHC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 7,259 | Yamada Kunio | www.rohto.co.jp |
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams.
Rohto Pharmaceutical Co.,Ltd. Fundamentals Summary
| RPHC.F fundamental statistics | |
|---|---|
| Market cap | US$5.48b |
| Earnings (TTM) | US$203.27m |
| Revenue (TTM) | US$1.86b |
27.0x
P/E Ratio2.9x
P/S RatioIs RPHC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPHC.F income statement (TTM) | |
|---|---|
| Revenue | JP¥278.03b |
| Cost of Revenue | JP¥117.44b |
| Gross Profit | JP¥160.59b |
| Other Expenses | JP¥130.26b |
| Earnings | JP¥30.33b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | 132.94 |
| Gross Margin | 57.76% |
| Net Profit Margin | 10.91% |
| Debt/Equity Ratio | 17.8% |
How did RPHC.F perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/09 04:00 |
| End of Day Share Price | 2024/07/12 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rohto Pharmaceutical Co.,Ltd. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |